

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.0	87.9	(35.2-181.0)	Male	5	5.8	86.3	(27.8-201.5)
Female	2	2.6	nc	(nc-nc)	Female	5	4.6	109.8	(35.4-256.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	5	1.4	367.2	(118.3-856.9)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.8	123.9	(45.2-269.7)
Female	26	32.1	81.0	(52.9-118.7)	Female	0	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	11.4	131.6	(73.6-217.1)	Female	4	3.1	nc	(nc-nc)
Female	8	9.3	86.4	(37.2-170.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	33.4	101.8	(70.5-142.2)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	9	4.5	198.7	(90.7-377.2)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	5.7	105.8	(38.6-230.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.0	nc	(nc-nc)	Female	7	7.1	98.5	(39.5-202.9)
Female	3	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	116.2	107.6	(89.5-128.2)
Male	2	2.4	nc	(nc-nc)	Female	96	103.8	92.5	(74.9-112.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	15.0	153.3	(97.1-230.0)					
Female	12	13.3	90.3	(46.6-157.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	25.1	79.8	(48.7-123.2)	Male	18	15.5	115.9	(68.6-183.1)
Female	8	9.2	87.3	(37.6-171.9)	Female	4	11.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	6	2.9	209.4	(76.5-455.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	19	13.4	141.3	(85.1-220.7)
Female	64	80.2	79.8	(61.5-101.9)	Female	8	11.5	69.5	(29.9-137.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.2	nc	(nc-nc)	Male	9	9.0	100.0	(45.6-189.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	33.0	78.8	(51.5-115.5)	Female	7	8.4	83.7	(33.5-172.5)
Female	19	32.3	58.9	(35.4-92.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.5	106.1	(45.7-209.1)
Male	6	6.3	95.8	(35.0-208.4)	Female	7	8.0	87.4	(35.0-180.1)
Female	1	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	78	87.9	88.7	(70.1-110.8)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	7	5.8	119.8	(48.0-246.8)
<u>Kidney & Renal Pelvis</u>					Female	2	3.7	nc	(nc-nc)
Male	9	11.8	76.0	(34.7-144.3)	<u>Testis</u>				
Female	3	6.8	nc	(nc-nc)	Male	5	3.7	136.9	(44.1-319.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.7	nc	(nc-nc)	Male	6	4.3	140.2	(51.2-305.1)
Female	1	1.0	nc	(nc-nc)	Female	5	11.9	42.1	(13.6-98.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	8.5	nc	(nc-nc)	Female	22	17.6	125.0	(78.3-189.3)
Female	6	6.4	94.5	(34.5-205.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	314	323.1	97.2	(86.7-108.5)
Male	4	5.8	nc	(nc-nc)	Female	237	295.1	80.3	(70.4-91.2)
Female	1	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	55	44.8	122.8	(92.5-159.8)					
Female	40	42.7	93.7	(66.9-127.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.0	114.9	(49.5-226.3)	Male	4	5.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	5	4.0	125.0	(40.3-291.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	24	28.2	85.0	(54.5-126.5)	Female	5	3.3	150.1	(48.4-350.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	6	3.2	188.0	(68.6-409.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.9	101.0	(48.4-185.8)	Female	3	2.7	nc	(nc-nc)
Female	8	8.6	93.5	(40.2-184.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	28.5	137.1	(97.4-187.4)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	8	4.9	162.9	(70.2-321.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.6	nc	(nc-nc)	Female	6	6.1	97.7	(35.7-212.6)
Female	4	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	114	100.3	113.7	(93.8-136.5)
Male	2	2.0	nc	(nc-nc)	Female	93	92.9	100.1	(80.8-122.6)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	13.1	99.3	(52.8-169.8)					
Female	11	12.1	91.2	(45.4-163.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	9	5.8	155.4	(70.9-295.0)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	6.0	99.2	(36.2-215.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	3.0	nc	(nc-nc)	Female	23	22.1	104.1	(66.0-156.3)
Female	5	2.6	194.6	(62.7-454.2)	Female	22	19.5	113.0	(70.8-171.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	37.3	96.5	(67.6-133.6)	Male	25	23.4	106.8	(69.1-157.7)
Female	14	14.3	98.1	(53.6-164.6)	Female	26	18.7	139.1	(90.9-203.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.0	170.3	(87.9-297.5)	Male	6	5.8	102.7	(37.5-223.5)
Female	6	5.8	103.3	(37.7-224.9)	Female	3	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	21	19.9	105.3	(65.2-161.0)
Female	130	135.6	95.9	(80.1-113.8)	Female	23	18.2	126.7	(80.3-190.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.4	92.6	(29.8-216.1)	Male	15	14.3	104.7	(58.6-172.7)
<u>Colon / Rectum</u>					Female	13	6.8	190.5	(101.3-325.8)
Male	37	49.7	74.4	(52.4-102.5)	<u>Ovary</u>				
Female	68	49.7	136.9	(106.3-173.6)	Female	9	13.8	65.2	(29.7-123.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	9.8	102.2	(48.9-187.9)	Male	11	11.4	96.1	(47.9-172.0)
Female	2	2.7	nc	(nc-nc)	Female	11	12.3	89.2	(44.5-159.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.9	206.9	(75.5-450.3)	Male	140	141.5	99.0	(83.2-116.8)
Female	4	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.7	115.5	(55.3-212.4)
Male	18	18.3	98.4	(58.3-155.5)	Female	5	5.5	90.7	(29.2-211.6)
Female	18	11.2	160.9	(95.3-254.3)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.6	131.4	(48.0-286.0)
Male	8	5.9	136.3	(58.7-268.5)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	1	6.4	nc	(nc-nc)
<u>Leukemia</u>					Female	24	20.1	119.4	(76.5-177.7)
Male	10	12.5	79.9	(38.3-146.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.8	81.6	(35.1-160.8)	Female	30	30.4	98.8	(66.7-141.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.2	108.4	(51.9-199.5)	Male	512	495.4	103.3	(94.6-112.7)
Female	4	3.3	nc	(nc-nc)	Female	518	479.3	108.1	(99.0-117.8)
<u>Lung and Bronchus</u>									
Male	85	68.4	124.2	(99.2-153.6)					
Female	77	68.5	112.3	(88.6-140.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	4.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	15.7	70.1	(35.0-125.5)
Male	0	0.3	nc	(nc-nc)	Female	9	13.2	67.9	(31.0-129.0)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.1	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1	2.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	15.2	85.7	(45.6-146.5)	Male	10	10.2	97.9	(46.8-180.0)
Female	5	5.6	89.8	(28.9-209.6)	Female	13	8.6	150.5	(80.1-257.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.7	80.4	(32.2-165.7)
Female	61	59.2	103.0	(78.7-132.3)	Female	9	7.5	120.1	(54.8-228.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	5	6.2	80.3	(25.9-187.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	20.8	86.7	(51.4-137.1)	Female	7	5.9	118.6	(47.5-244.3)
Female	25	19.4	128.6	(83.2-189.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.7	127.5	(46.6-277.5)
Male	9	4.1	219.9	(100.3-417.5)	Female	5	4.8	104.7	(33.8-244.4)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	58.1	96.4	(72.8-125.2)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.1	nc	(nc-nc)
Male	11	7.9	139.2	(69.4-249.0)	<u>Testis</u>				
Female	11	4.7	232.8	(116.1-416.6)	Male	3	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.4	nc	(nc-nc)	Male	6	3.0	197.3	(72.0-429.5)
Female	1	0.7	nc	(nc-nc)	Female	9	10.3	87.4	(39.9-166.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.5	nc	(nc-nc)	Female	15	13.1	114.8	(64.2-189.3)
Female	4	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	202	208.5	96.9	(84.0-111.2)
Male	2	4.0	nc	(nc-nc)	Female	217	203.0	106.9	(93.2-122.1)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	28.1	96.2	(63.4-140.0)					
Female	27	27.5	98.2	(64.7-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.7	104.8	(42.0-215.9)	Male	3	4.4	nc	(nc-nc)
Female	6	2.2	268.5	(98.0-584.3)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	37	24.1	153.4	(108.0-211.5)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	9.1	120.5	(60.0-215.5)	Female	0	2.4	nc	(nc-nc)
Female	6	7.7	78.4	(28.6-170.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	1.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	26	26.6	97.7	(63.8-143.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	3.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	2.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.8	nc	(nc-nc)	Female	6	5.5	109.5	(40.0-238.4)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	15	12.5	120.4	(67.3-198.5)	Male	92	92.2	99.7	(80.4-122.3)
Female	10	11.2	89.5	(42.9-164.7)	Female	80	81.5	98.2	(77.9-122.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	5.9	118.6	(47.5-244.4)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	6.4	78.2	(25.2-182.4)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	17	22.1	76.9	(44.7-123.1)
Male	0	0.4	nc	(nc-nc)	Female	20	19.3	103.4	(63.2-159.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.3	107.2	(53.4-191.8)	Male	8	5.9	134.5	(57.9-265.1)
Female	7	4.2	167.4	(67.1-345.0)	Female	7	4.9	142.9	(57.3-294.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	95.6	(30.8-223.2)
Female	44	35.6	123.4	(89.7-165.7)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	13.4	157.2	(97.3-240.4)	Female	3	3.7	nc	(nc-nc)
Female	17	15.0	113.6	(66.1-181.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	47	35.0	134.4	(98.7-178.7)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.3	nc	(nc-nc)	Female	6	7.9	76.1	(27.8-165.7)
Female	3	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	147	128.0	114.9	(97.0-135.0)
Male	2	2.3	nc	(nc-nc)	Female	136	131.8	103.1	(86.5-122.0)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	18.1	127.3	(80.7-191.0)					
Female	21	19.2	109.6	(67.8-167.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	22.9	74.3	(43.3-119.0)	Male	6	13.5	44.5	(16.3-97.0)
Female	9	9.4	95.9	(43.8-182.0)	Female	10	11.4	87.7	(42.0-161.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	5	3.5	144.6	(46.6-337.5)
Female	4	3.5	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	11.8	84.6	(40.5-155.6)
Female	108	80.2	134.7	(110.5-162.6)	Female	11	11.8	93.1	(46.4-166.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.1	191.7	(70.0-417.3)	Male	11	7.8	140.7	(70.1-251.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	29.8	73.9	(46.3-111.9)	Female	6	8.5	70.9	(25.9-154.4)
Female	28	34.0	82.3	(54.7-119.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.8	102.7	(41.2-211.7)
Male	9	5.6	162.0	(73.9-307.5)	Female	11	8.3	132.1	(65.9-236.5)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	76.7	75.6	(57.4-97.8)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	7	5.3	131.9	(52.8-271.8)
<u>Kidney & Renal Pelvis</u>					Female	2	3.9	nc	(nc-nc)
Male	8	10.3	77.8	(33.5-153.3)	<u>Testis</u>				
Female	5	6.8	73.3	(23.6-171.1)	Male	2	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.3	184.2	(67.3-400.9)	Male	4	3.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	7	11.4	61.6	(24.7-126.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.6	nc	(nc-nc)	Female	19	17.6	108.2	(65.1-169.0)
Female	3	6.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	256	285.2	89.8	(79.1-101.5)
Male	4	5.1	nc	(nc-nc)	Female	295	298.2	98.9	(87.9-110.9)
Female	3	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	39.9	135.3	(101.6-176.5)					
Female	40	42.5	94.1	(67.2-128.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	91.0	(36.4-187.5)	Male	6	5.8	103.8	(37.9-225.9)
Female	3	2.6	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	5	1.5	333.7	(107.5-778.7)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	42	32.8	128.1	(92.3-173.2)	Female	1	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	11.1	126.2	(68.9-211.8)	Female	1	3.1	nc	(nc-nc)
Female	7	9.1	76.6	(30.7-157.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	31	31.0	100.1	(68.0-142.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	4.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	5	1.5	324.5	(104.6-757.2)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	3.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	12	6.1	197.1	(101.8-344.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.3	nc	(nc-nc)	Female	10	7.0	142.9	(68.4-262.8)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	14.4	41.7	(15.2-90.7)	Male	100	112.4	88.9	(72.4-108.2)
Female	13	13.0	100.3	(53.4-171.6)	Female	121	105.0	115.3	(95.6-137.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.1	81.7	(26.3-190.8)	Male	4	4.2	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	23	23.4	98.4	(62.3-147.6)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	8.4	59.4	(19.2-138.7)	Female	1	2.3	nc	(nc-nc)
Female	6	7.1	84.3	(30.8-183.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	23	24.5	93.9	(59.5-140.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	3.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	5	4.0	125.4	(40.4-292.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	7	5.1	136.7	(54.8-281.6)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	11.5	156.0	(92.4-246.6)	Male	81	85.9	94.3	(74.9-117.3)
Female	13	10.3	126.7	(67.4-216.7)	Female	79	77.3	102.2	(80.9-127.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.6	78.9	(28.8-171.8)	Male	2	4.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	20	24.0	83.5	(51.0-129.0)	Female	5	3.5	142.9	(46.0-333.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	9.7	185.6	(109.9-293.3)	Female	6	2.5	238.9	(87.2-520.0)
Female	8	10.1	79.3	(34.1-156.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	6	2.5	242.5	(88.5-527.7)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	24.8	125.2	(85.0-177.7)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	90	92.1	97.7	(78.6-120.1)
Male	1	1.6	nc	(nc-nc)	Female	99	88.7	111.7	(90.7-135.9)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	13.2	45.4	(16.6-98.7)					
Female	14	12.8	109.0	(59.5-182.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.5	117.0	(56.0-215.1)	Male	4	5.5	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	4.7	214.7	(102.8-394.9)
Female	26	31.7	82.1	(53.6-120.3)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	6	3.3	179.7	(65.6-391.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.4	96.1	(47.9-172.0)	Female	4	3.2	nc	(nc-nc)
Female	14	10.6	131.6	(71.9-220.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	26	32.8	79.4	(51.8-116.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.3	117.5	(37.9-274.2)	Female	4	7.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Male	111	114.8	96.7	(79.5-116.4)
Female	2	0.4	nc	(nc-nc)	Female	107	109.1	98.1	(80.4-118.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	15.7	95.5	(53.4-157.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	15.5	122.9	(73.9-191.9)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.4	(42.8-195.8)	Male	10	5.4	186.0	(89.1-342.1)
Female	1	2.5	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	34	28.6	119.0	(82.4-166.4)	Female	6	3.4	175.9	(64.2-382.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	10.9	164.5	(97.4-260.0)	Female	6	2.8	215.0	(78.5-467.9)
Female	11	8.7	126.3	(63.0-226.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	30.6	107.8	(74.2-151.3)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	0	4.2	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.2	225.9	(72.8-527.3)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Female	8	6.3	127.9	(55.1-252.0)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	113	109.9	102.8	(84.7-123.6)
Male	3	2.1	nc	(nc-nc)	Female	104	95.2	109.2	(89.3-132.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	14.8	47.2	(18.9-97.2)					
Female	7	12.6	55.4	(22.2-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.1	98.4	(35.9-214.2)	Male	2	4.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	31	22.5	138.0	(93.8-195.9)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	8.3	96.5	(41.6-190.2)	Female	2	2.2	nc	(nc-nc)
Female	12	7.7	155.1	(80.1-271.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.9	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	24.4	90.2	(56.5-136.6)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.1	nc	(nc-nc)	Female	7	5.0	138.7	(55.6-285.7)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	63	83.7	75.3	(57.8-96.3)
Male	1	1.6	nc	(nc-nc)	Female	87	76.8	113.2	(90.7-139.7)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	11.3	70.6	(30.4-139.2)					
Female	9	10.5	85.9	(39.2-163.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	5.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	17.1	40.8	(16.4-84.1)
Male	0	0.3	nc	(nc-nc)	Female	7	13.9	50.2	(20.1-103.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	2.3	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	12.5	167.9	(103.9-256.6)	Male	12	8.8	136.8	(70.6-239.0)
Female	10	5.0	200.3	(95.9-368.3)	Female	8	7.4	107.6	(46.3-212.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	5	2.4	212.2	(68.4-495.3)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.4	122.0	(55.7-231.7)
Female	44	53.9	81.6	(59.3-109.5)	Female	7	6.7	105.0	(42.1-216.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	17.6	91.1	(52.0-148.0)	Female	9	5.3	169.1	(77.2-321.1)
Female	20	17.4	115.2	(70.4-178.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.0	nc	(nc-nc)
Male	6	3.6	167.3	(61.1-364.1)	Female	7	4.3	163.8	(65.6-337.6)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	52.2	107.2	(81.0-139.2)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.9	nc	(nc-nc)
Male	9	6.9	130.4	(59.5-247.6)	<u>Testis</u>				
Female	6	4.3	141.0	(51.5-306.8)	Male	1	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	16	8.6	185.4	(105.9-301.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.6	108.5	(35.0-253.1)	Female	10	12.1	82.8	(39.7-152.3)
Female	5	3.7	136.8	(44.1-319.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	185	179.7	102.9	(88.6-118.9)
Male	1	3.5	nc	(nc-nc)	Female	183	181.7	100.7	(86.6-116.4)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	23.6	71.9	(41.9-115.2)					
Female	15	24.8	60.4	(33.8-99.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.4	142.2	(73.4-248.5)	Male	6	6.1	98.8	(36.1-215.0)
Female	3	2.9	nc	(nc-nc)	Female	7	4.9	142.6	(57.1-293.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	1.4	356.3	(114.8-831.4)
Female	3	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	41	34.7	118.2	(84.8-160.4)	Female	7	4.1	172.7	(69.2-355.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	11.9	151.2	(89.6-239.0)	Female	4	3.4	nc	(nc-nc)
Female	11	10.2	108.3	(54.0-193.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.7	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	36.1	108.0	(76.8-147.6)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.7	188.0	(60.6-438.8)	Male	5	1.5	329.7	(106.2-769.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	14	6.1	231.3	(126.4-388.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.1	nc	(nc-nc)	Female	9	7.8	115.6	(52.7-219.4)
Female	2	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	123.5	107.7	(90.2-127.7)
Male	2	2.4	nc	(nc-nc)	Female	145	113.7	127.5	(107.6-150.0)
Female	2	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	16.1	99.2	(56.6-161.1)					
Female	20	14.9	134.1	(81.9-207.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	13	10.2	127.9	(68.0-218.7)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	3.9	181.0	(72.5-373.0)	Female	0	1.0	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	12	10.9	110.6	(57.1-193.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	5.3	132.4	(53.0-272.8)	Male	46	38.6	119.3	(87.3-159.1)
Female	4	5.1	nc	(nc-nc)	Female	33	35.9	91.8	(63.2-128.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.6	124.1	(49.7-255.8)	Male	5	4.4	112.6	(36.3-262.7)
Female	1	1.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	19	20.3	93.6	(56.3-146.2)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.4	107.3	(48.9-203.6)	Female	2	1.9	nc	(nc-nc)
Female	9	5.4	167.1	(76.2-317.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	24.8	137.3	(95.1-191.9)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	6	4.6	131.0	(47.8-285.1)
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	90	86.1	104.6	(84.1-128.5)
Male	3	1.8	nc	(nc-nc)	Female	55	63.1	87.2	(65.7-113.5)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	10.7	83.9	(38.3-159.2)					
Female	3	7.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	27.3	120.7	(83.1-169.6)	Male	30	13.9	215.3	(145.3-307.4)
Female	10	10.3	97.3	(46.6-179.0)	Female	23	10.4	221.8	(140.6-332.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	7	3.3	212.5	(85.1-437.8)	Female	0	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	16	12.5	128.0	(73.1-208.0)
Female	80	78.0	102.6	(81.4-127.7)	Female	9	12.2	73.6	(33.6-139.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	9	7.6	117.7	(53.7-223.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	33.6	80.4	(53.0-117.0)	Female	5	8.4	59.6	(19.2-139.1)
Female	38	35.7	106.3	(75.2-145.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.9	139.6	(69.6-249.8)
Male	7	6.1	114.1	(45.7-235.0)	Female	16	9.0	177.7	(101.5-288.6)
Female	0	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	113	85.9	131.6	(108.4-158.2)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	4.1	nc	(nc-nc)
Male	7	10.8	64.8	(26.0-133.5)	<u>Testis</u>				
Female	6	7.1	84.5	(30.8-183.8)	Male	7	1.5	458.9	(183.8-945.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	8.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	8.1	61.4	(19.8-143.4)	Female	19	17.4	109.0	(65.6-170.2)
Female	5	6.4	77.6	(25.0-181.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	353	315.8	111.8	(100.4-124.1)
Male	5	5.2	96.7	(31.2-225.6)	Female	302	301.6	100.1	(89.1-112.1)
Female	1	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	39	47.3	82.5	(58.7-112.8)					
Female	43	47.3	90.8	(65.7-122.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	4.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	22	15.6	141.0	(88.4-213.6)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.2	97.0	(35.4-211.0)	Female	2	1.6	nc	(nc-nc)
Female	7	5.7	122.6	(49.1-252.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	18	17.6	102.3	(60.6-161.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.7	nc	(nc-nc)	Male	55	61.2	89.8	(67.7-116.9)
Female	0	0.2	nc	(nc-nc)	Female	58	54.9	105.6	(80.2-136.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	8.5	58.7	(18.9-136.9)	<u>All Sites / Types</u>				
Female	5	7.9	63.1	(20.3-147.3)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	58.8	95.3	(72.0-123.8)	Male	30	37.3	80.4	(54.2-114.7)
Female	24	24.0	100.0	(64.1-148.8)	Female	28	32.8	85.2	(56.6-123.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.9	100.7	(52.0-176.0)	Male	6	9.1	65.9	(24.0-143.3)
Female	4	10.4	nc	(nc-nc)	Female	5	7.6	65.9	(21.2-153.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	25	32.3	77.4	(50.1-114.3)
Female	199	225.4	88.3	(76.4-101.4)	Female	28	31.1	90.1	(59.9-130.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	9.8	71.6	(28.7-147.6)	Male	23	21.8	105.4	(66.8-158.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	86	78.0	110.3	(88.2-136.2)	Female	23	23.2	99.3	(62.9-149.0)
Female	83	85.0	97.6	(77.7-121.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	17.8	118.0	(73.0-180.4)
Male	18	14.9	120.8	(71.5-190.9)	Female	13	20.9	62.2	(33.1-106.3)
Female	7	4.5	154.1	(61.7-317.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	197	208.5	94.5	(81.7-108.6)
Male	4	5.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	4.6	nc	(nc-nc)	Male	10	13.8	72.6	(34.7-133.5)
<u>Kidney & Renal Pelvis</u>					Female	6	9.6	62.8	(22.9-136.6)
Male	28	28.4	98.6	(65.5-142.5)	<u>Testis</u>				
Female	19	18.7	101.8	(61.2-158.9)	Male	17	9.3	183.0	(106.5-293.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	8.8	102.0	(46.5-193.6)	Male	10	10.5	95.0	(45.5-174.8)
Female	3	2.7	nc	(nc-nc)	Female	26	36.4	71.5	(46.7-104.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	20.9	110.2	(69.8-165.4)	Female	54	49.3	109.5	(82.2-142.9)
Female	21	17.5	120.3	(74.4-183.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	771	768.9	100.3	(93.3-107.6)
Male	14	14.0	100.2	(54.7-168.1)	Female	739	810.3	91.2	(84.7-98.0)
Female	8	5.5	144.2	(62.1-284.2)					
<u>Lung and Bronchus</u>									
Male	114	105.1	108.5	(89.5-130.3)					
Female	115	112.9	101.9	(84.1-122.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	2	7.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	3.9	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	13.0	53.9	(21.6-111.0)
Male	0	0.3	nc	(nc-nc)	Female	4	9.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	24.7	52.7	(28.0-90.1)	Male	35	15.7	223.3	(155.5-310.6)
Female	13	9.7	133.8	(71.2-228.8)	Female	20	12.9	155.1	(94.7-239.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	19	13.3	142.5	(85.8-222.6)
Female	100	95.8	104.3	(84.9-126.9)	Female	15	12.5	120.0	(67.1-198.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	5	9.9	50.5	(16.3-117.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	33.2	99.4	(68.4-139.5)	Female	2	9.6	nc	(nc-nc)
Female	34	33.9	100.2	(69.4-140.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.7	91.1	(36.5-187.6)
Male	7	6.7	104.8	(42.0-216.0)	Female	12	8.4	143.2	(73.9-250.1)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	97.3	90.5	(72.5-111.4)
Male	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.7	nc	(nc-nc)
Male	9	12.5	72.2	(32.9-137.0)	<u>Testis</u>				
Female	12	7.8	153.9	(79.4-268.8)	Male	7	2.8	253.4	(101.5-522.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.0	nc	(nc-nc)	Male	5	4.3	116.7	(37.6-272.4)
Female	1	1.2	nc	(nc-nc)	Female	20	13.9	143.8	(87.8-222.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	8.4	107.2	(48.9-203.4)	Female	20	21.7	92.2	(56.3-142.4)
Female	4	6.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	301	334.0	90.1	(80.2-100.9)
Male	5	6.3	79.2	(25.5-184.8)	Female	340	332.8	102.2	(91.6-113.6)
Female	1	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	45.8	61.1	(40.6-88.4)					
Female	45	47.0	95.8	(69.8-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	5	1.3	391.0	(126.0-912.4)
Female	0	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	11	6.7	163.7	(81.6-292.9)	Female	4	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	7.9	139.4	(69.5-249.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	3.6	nc	(nc-nc)	Male	35	26.8	130.7	(91.0-181.7)
Female	3	3.1	nc	(nc-nc)	Female	30	22.6	132.7	(89.5-189.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.4	97.4	(51.8-166.5)	Male	6	8.2	73.5	(26.8-160.0)
Female	6	4.8	124.8	(45.6-271.6)	Female	12	6.3	191.0	(98.6-333.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.0	114.3	(49.2-225.3)
Female	47	45.8	102.7	(75.4-136.5)	Female	4	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	4.9	143.7	(57.6-296.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	17.5	74.3	(39.5-127.1)	Female	4	4.6	nc	(nc-nc)
Female	16	16.2	99.1	(56.6-160.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.1	nc	(nc-nc)
Male	9	3.4	262.6	(119.8-498.5)	Female	6	4.1	146.4	(53.5-318.6)
Female	3	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	49.8	72.2	(50.6-100.0)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	3.1	195.5	(71.4-425.6)
<u>Kidney & Renal Pelvis</u>					Female	3	1.8	nc	(nc-nc)
Male	8	6.4	125.5	(54.0-247.3)	<u>Testis</u>				
Female	2	3.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.1	242.7	(78.2-566.4)	Male	6	2.2	273.7	(100.0-595.9)
Female	1	0.6	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.4	nc	(nc-nc)	Female	11	10.4	106.0	(52.8-189.7)
Female	3	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	174	174.8	99.5	(85.3-115.5)
Male	1	3.2	nc	(nc-nc)	Female	172	161.6	106.4	(91.1-123.6)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	24.6	138.2	(95.7-193.2)					
Female	34	23.9	142.5	(98.7-199.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	19.4	82.5	(47.1-133.9)	Male	13	12.3	105.6	(56.2-180.6)
Female	7	6.9	101.5	(40.7-209.2)	Female	10	9.5	105.1	(50.3-193.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	5	3.1	163.3	(52.6-381.2)
Female	3	3.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	10	10.5	94.8	(45.4-174.4)
Female	62	69.2	89.6	(68.7-114.9)	Female	10	9.0	111.1	(53.2-204.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	10	7.7	130.4	(62.4-239.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	26.2	53.5	(29.2-89.7)	Female	11	6.9	158.5	(79.0-283.7)
Female	20	24.3	82.2	(50.2-127.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.0	166.6	(79.8-306.4)
Male	2	5.2	nc	(nc-nc)	Female	5	6.0	83.4	(26.9-194.7)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	73.6	100.5	(78.9-126.1)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.7	nc	(nc-nc)
Male	11	9.7	113.4	(56.5-202.9)	<u>Testis</u>				
Female	2	5.6	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male	6	3.4	177.4	(64.8-386.2)
Female	0	0.8	nc	(nc-nc)	Female	13	10.5	124.1	(66.0-212.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.6	105.4	(42.2-217.1)	Female	10	15.4	65.1	(31.2-119.7)
Female	3	4.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	238	259.3	91.8	(80.5-104.2)
Male	4	4.9	nc	(nc-nc)	Female	210	239.5	87.7	(76.2-100.4)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	35.4	70.5	(45.6-104.1)					
Female	21	33.3	63.0	(39.0-96.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	3	7.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	3.2	155.6	(50.1-363.1)	Female	1	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	9.2	87.4	(37.6-172.2)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	32.5	89.4	(59.8-128.3)
Male	0	0.6	nc	(nc-nc)	Female	18	25.5	70.7	(41.9-111.7)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.2	nc	(nc-nc)					
Female	3	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	11.9	100.7	(52.0-175.9)	Male	7	8.7	80.8	(32.4-166.5)
Female	8	4.1	193.2	(83.2-380.7)	Female	8	7.0	114.6	(49.3-225.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	5	2.2	228.7	(73.7-533.7)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	54	50.7	106.5	(80.0-139.0)	Female	8	5.7	140.0	(60.3-275.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	8	5.7	141.3	(60.8-278.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	17.0	105.7	(62.6-167.1)	Female	5	4.8	103.1	(33.2-240.6)
Female	11	14.3	76.7	(38.2-137.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.8	129.9	(41.9-303.2)
Male	4	3.5	nc	(nc-nc)	Female	9	3.5	256.4	(117.0-486.8)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	69	51.2	134.8	(104.9-170.6)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.5	nc	(nc-nc)
Male	7	6.8	102.2	(41.0-210.7)	<u>Testis</u>				
Female	3	3.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	11	8.7	127.0	(63.3-227.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	8	11.3	70.9	(30.5-139.6)
Female	1	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	175.3	110.1	(95.1-126.8)
Male	3	3.5	nc	(nc-nc)	Female	166	163.1	101.8	(86.9-118.5)
Female	3	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	22.8	87.7	(53.6-135.5)					
Female	14	21.2	66.1	(36.1-110.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	44.1	83.8	(59.0-115.6)	Male	13	26.0	50.0	(26.6-85.5)
Female	15	18.0	83.3	(46.6-137.4)	Female	18	22.7	79.4	(47.1-125.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.2	73.3	(26.8-159.5)	Male	7	6.6	105.4	(42.2-217.2)
Female	8	7.4	108.5	(46.7-213.8)	Female	6	5.6	106.7	(39.0-232.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	25	23.0	108.8	(70.4-160.6)
Female	146	155.5	93.9	(79.3-110.4)	Female	22	22.8	96.6	(60.5-146.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.4	93.6	(34.2-203.7)	Male	19	14.9	127.5	(76.7-199.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	54	57.0	94.7	(71.1-123.5)	Female	14	16.4	85.3	(46.6-143.2)
Female	69	64.3	107.3	(83.5-135.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	13.1	129.4	(75.4-207.3)
Male	15	10.7	140.0	(78.3-230.9)	Female	14	15.8	88.7	(48.4-148.8)
Female	2	3.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	135	149.6	90.2	(75.6-106.8)
Male	4	3.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.2	nc	(nc-nc)	Male	8	10.2	78.6	(33.8-154.8)
<u>Kidney & Renal Pelvis</u>					Female	7	7.3	95.3	(38.2-196.3)
Male	10	19.9	50.3	(24.1-92.5)	<u>Testis</u>				
Female	15	13.3	113.1	(63.3-186.6)	Male	4	5.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	6.3	126.8	(54.6-249.8)	Male	5	6.8	74.0	(23.8-172.6)
Female	2	1.9	nc	(nc-nc)	Female	12	23.6	50.9	(26.3-88.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	15.2	85.6	(45.5-146.4)	Female	41	34.1	120.1	(86.2-162.9)
Female	13	12.9	100.7	(53.6-172.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	501	554.2	90.4	(82.7-98.7)
Male	12	9.7	123.5	(63.8-215.8)	Female	544	579.3	93.9	(86.2-102.1)
Female	3	4.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	72	77.8	92.5	(72.4-116.5)					
Female	88	82.3	106.9	(85.8-131.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.2	151.8	(75.7-271.6)	Male	4	4.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	24	25.9	92.8	(59.5-138.1)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	9.5	52.5	(16.9-122.5)	Female	1	2.6	nc	(nc-nc)
Female	11	9.8	111.8	(55.8-200.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.2	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	24.6	97.8	(62.6-145.5)
Male	3	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	7	3.4	207.3	(83.1-427.2)	<u>Testis</u>				
Female	0	2.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.5	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	84	91.8	91.5	(72.9-113.2)
Male	0	1.7	nc	(nc-nc)	Female	73	92.3	79.1	(62.0-99.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	12.8	77.9	(37.3-143.3)					
Female	8	12.9	61.8	(26.6-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.5	105.2	(50.4-193.5)	Male	7	7.4	94.1	(37.7-193.9)
Female	1	3.5	nc	(nc-nc)	Female	7	6.4	109.6	(43.9-225.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	6.3	144.0	(65.7-273.3)
Female	59	43.5	135.6	(103.2-174.9)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	14.0	107.1	(59.9-176.7)	Female	4	4.1	nc	(nc-nc)
Female	10	12.6	79.3	(37.9-145.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.1	227.9	(91.3-469.6)
Male	1	2.8	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	38.7	111.2	(80.5-149.8)
Male	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	3.2	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	15	8.2	182.2	(101.9-300.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.9	nc	(nc-nc)	Female	9	9.0	99.5	(45.4-188.8)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	142.0	93.7	(78.4-111.0)
Male	4	2.9	nc	(nc-nc)	Female	147	140.7	104.4	(88.2-122.8)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	17.9	50.4	(23.0-95.7)					
Female	14	17.1	81.7	(44.6-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	2.9	307.2	(140.2-583.1)	Male	1	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	21	12.7	165.6	(102.4-253.1)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	4.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.0	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	12.6	142.3	(84.3-224.9)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.4	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	58	44.9	129.1	(98.0-166.8)
Male	0	0.9	nc	(nc-nc)	Female	46	40.5	113.7	(83.2-151.7)
Female	0	0.2	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	8	5.7	141.4	(60.9-278.7)	<u>Bladder, Urinary</u>				
Female	5	4.8	103.1	(33.2-240.6)	Male	9	2.9	307.2	(140.2-583.1)
					Female	1	1.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	18.9	84.5	(48.2-137.2)	Male	9	12.7	70.8	(32.3-134.4)
Female	11	7.1	154.9	(77.2-277.2)	Female	10	10.2	98.2	(47.0-180.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	10.7	55.9	(20.4-121.6)
Female	69	72.7	94.9	(73.9-120.1)	Female	13	9.3	140.0	(74.4-239.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.1	160.8	(51.8-375.3)	Male	5	7.9	63.7	(20.5-148.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	25.9	85.1	(53.3-128.8)	Female	8	7.3	110.2	(47.4-217.1)
Female	33	24.2	136.1	(93.7-191.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	5.9	168.6	(80.7-310.1)
Male	2	5.2	nc	(nc-nc)	Female	5	6.0	82.7	(26.7-193.0)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	71	75.1	94.6	(73.9-119.3)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	6	2.6	227.1	(82.9-494.2)
Male	9	9.9	90.7	(41.4-172.2)	<u>Testis</u>				
Female	5	5.9	84.7	(27.3-197.7)	Male	4	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	9	11.7	76.8	(35.1-145.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.7	104.6	(41.9-215.4)	Female	12	16.3	73.6	(38.0-128.6)
Female	3	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	239	262.4	91.1	(79.9-103.4)
Male	4	5.0	nc	(nc-nc)	Female	254	250.4	101.4	(89.3-114.7)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	35.4	130.0	(95.2-173.5)					
Female	34	35.4	96.1	(66.6-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.4	120.9	(67.6-199.5)	Male	11	8.3	133.2	(66.4-238.4)
Female	6	4.3	139.9	(51.1-304.6)	Female	10	6.6	152.0	(72.8-279.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	5	2.0	251.6	(81.1-587.0)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	7	6.9	101.1	(40.5-208.3)
Female	49	48.0	102.0	(75.5-134.9)	Female	10	5.7	174.0	(83.3-320.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	9	5.2	173.5	(79.1-329.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.0	111.6	(67.2-174.3)	Female	7	4.7	149.1	(59.7-307.2)
Female	21	14.6	143.9	(89.0-219.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.9	nc	(nc-nc)
Male	5	3.4	145.8	(47.0-340.2)	Female	5	3.6	138.1	(44.5-322.2)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	50.1	109.8	(82.7-142.9)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	10	6.5	153.3	(73.4-282.0)	<u>Testis</u>				
Female	7	3.7	186.9	(74.9-385.0)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	12	7.8	154.4	(79.7-269.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.3	117.2	(37.8-273.4)	Female	13	10.9	118.8	(63.2-203.1)
Female	8	3.0	263.0	(113.3-518.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	216	172.2	125.5	(109.3-143.4)
Male	4	3.3	nc	(nc-nc)	Female	217	159.1	136.4	(118.8-155.8)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	23.3	128.8	(86.9-183.9)					
Female	32	21.9	146.2	(100.0-206.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.1	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	8	7.8	102.7	(44.2-202.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	8.8	91.4	(39.3-180.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	1.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	3.9	153.0	(55.9-333.0)	Male	37	30.3	122.3	(86.1-168.5)
Female	4	3.5	nc	(nc-nc)	Female	26	26.3	99.0	(64.7-145.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	16.0	81.2	(43.2-138.8)	Male	12	10.1	118.2	(61.0-206.6)
Female	7	6.5	107.1	(42.9-220.7)	Female	15	8.5	177.1	(99.1-292.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	163.0	(52.5-380.4)	Male	2	2.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.7	126.9	(63.3-227.1)
Female	69	62.3	110.7	(86.1-140.1)	Female	12	8.3	143.8	(74.2-251.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	13	6.3	205.0	(109.1-350.7)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	18	21.6	83.4	(49.4-131.7)	<u>Ovary</u>				
Female	37	23.0	160.6	(113.0-221.3)	Female	9	6.3	142.3	(64.9-270.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.3	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	8	5.7	140.9	(60.7-277.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	87	61.4	141.7	(113.5-174.8)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.7	161.1	(58.8-350.6)
Male	9	8.1	111.7	(51.0-212.1)	Female	4	2.6	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.0	89.3	(38.5-176.0)
Male	8	5.4	148.4	(63.9-292.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	15	13.9	108.0	(60.4-178.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	241	214.7	112.3	(98.5-127.4)
Female	3	1.5	nc	(nc-nc)	Female	252	219.4	114.9	(101.1-129.9)
<u>Lung and Bronchus</u>									
Male	23	29.6	77.8	(49.3-116.7)					
Female	31	31.1	99.6	(67.7-141.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	14.0	50.2	(20.1-103.3)	Male	12	8.6	139.3	(71.9-243.3)
Female	14	5.2	268.9	(146.9-451.1)	Female	5	7.0	71.2	(23.0-166.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	7.5	173.9	(92.5-297.4)
Female	48	49.4	97.2	(71.7-128.9)	Female	5	6.7	74.7	(24.1-174.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	6	5.1	117.8	(43.0-256.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	18.4	86.8	(49.6-140.9)	Female	6	5.0	119.4	(43.6-259.9)
Female	20	18.5	108.3	(66.1-167.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.2	142.2	(51.9-309.5)
Male	3	3.5	nc	(nc-nc)	Female	8	4.5	176.7	(76.1-348.3)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	49.5	111.2	(83.8-144.8)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.1	nc	(nc-nc)
Male	7	6.7	105.0	(42.1-216.4)	<u>Testis</u>				
Female	5	4.1	123.1	(39.7-287.3)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	7.7	77.8	(28.4-169.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.8	125.3	(45.8-272.8)	Female	17	10.8	158.1	(92.1-253.2)
Female	5	3.8	133.3	(43.0-311.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	187	180.5	103.6	(89.3-119.5)
Male	2	3.3	nc	(nc-nc)	Female	186	175.8	105.8	(91.2-122.2)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	25.1	107.7	(71.0-156.8)					
Female	22	24.5	89.9	(56.3-136.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.4	105.3	(52.5-188.5)	Male	8	7.0	114.1	(49.1-224.8)
Female	6	4.0	151.1	(55.2-328.8)	Female	5	5.7	87.1	(28.1-203.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
Female	37	40.5	91.3	(64.3-125.9)	Female	7	5.2	134.4	(53.8-276.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	8	4.4	183.8	(79.1-362.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	14.3	132.9	(80.0-207.6)	Female	1	4.1	nc	(nc-nc)
Female	16	14.1	113.4	(64.8-184.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	47	40.8	115.2	(84.6-153.2)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	5	1.6	317.2	(102.2-740.3)
Female	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.5	164.5	(75.0-312.2)	Female	6	8.8	68.0	(24.8-148.0)
Female	2	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.7	nc	(nc-nc)	Male	155	143.9	107.7	(91.4-126.1)
Female	0	0.5	nc	(nc-nc)	Female	134	139.9	95.8	(80.2-113.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	22	19.3	114.1	(71.5-172.8)	<u>All Sites / Types</u>				
Female	23	18.9	121.7	(77.1-182.6)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	105.3	(38.5-229.2)	Male	3	4.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	22	20.7	106.0	(66.4-160.6)	Female	0	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.9	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.1	85.9	(34.4-177.0)	Female	1	2.1	nc	(nc-nc)
Female	11	7.3	150.3	(74.9-268.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	27	22.8	118.4	(78.0-172.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	3.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	7	1.6	424.8	(170.2-875.4)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	5	3.5	142.2	(45.8-331.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	10	4.6	219.6	(105.1-403.9)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	10.5	151.7	(86.6-246.3)	Male	84	83.4	100.7	(80.3-124.7)
Female	14	9.7	144.3	(78.8-242.1)	Female	90	72.5	124.2	(99.9-152.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.6	139.3	(44.9-325.2)	Male	7	2.3	302.8	(121.3-623.8)
Female	1	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	24	11.7	204.6	(131.1-304.5)	Female	4	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	4.8	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	14.0	128.3	(76.0-202.8)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	60	48.7	123.3	(94.1-158.7)
Male	1	0.9	nc	(nc-nc)	Female	62	39.8	155.9	(119.5-199.9)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	6.7	90.1	(32.9-196.2)					
Female	7	5.5	127.7	(51.1-263.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	55.0	94.5	(70.6-124.0)	Male	16	37.6	42.5	(24.3-69.1)
Female	22	22.3	98.5	(61.7-149.1)	Female	11	35.0	31.5	(15.7-56.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	13.5	125.7	(73.2-201.3)	Male	8	8.7	92.0	(39.6-181.2)
Female	8	11.9	67.2	(29.0-132.5)	Female	9	7.1	127.1	(58.0-241.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.7	nc	(nc-nc)	Male	25	32.6	76.6	(49.6-113.1)
Female	167	225.5	74.0	(63.2-86.2)	Female	26	30.1	86.4	(56.4-126.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	20	11.0	182.6	(111.5-282.1)	Male	24	21.8	110.2	(70.6-163.9)
Female					Female	9	11.3	79.5	(36.3-150.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	71	74.5	95.3	(74.4-120.2)	Female	15	23.1	65.0	(36.4-107.3)
Female	78	79.3	98.4	(77.8-122.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	16.8	119.0	(72.7-183.9)
Male	11	14.3	76.9	(38.4-137.7)	Female	27	19.3	139.7	(92.0-203.2)
Female	4	4.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	225	199.6	112.7	(98.5-128.5)
Male	6	7.2	83.5	(30.5-181.7)	<u>Stomach</u>				
Female	8	6.0	134.2	(57.8-264.5)	Male	20	13.1	152.9	(93.4-236.2)
<u>Kidney & Renal Pelvis</u>					Female	5	8.9	56.2	(18.1-131.2)
Male	18	28.1	64.0	(37.9-101.2)	<u>Testis</u>				
Female	12	18.4	65.4	(33.7-114.2)	Male	4	12.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	14	8.5	165.0	(90.2-276.9)	Male	5	11.5	43.4	(14.0-101.3)
Female	5	2.6	189.1	(60.9-441.3)	Female	32	41.9	76.3	(52.2-107.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	22.1	76.8	(44.7-122.9)	Female	47	48.9	96.1	(70.6-127.8)
Female	19	18.4	103.2	(62.1-161.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	719	752.1	95.6	(88.7-102.9)
Male	15	13.8	108.5	(60.7-179.0)	Female	683	801.6	85.2	(78.9-91.8)
Female	9	5.4	167.5	(76.4-318.0)					
<u>Lung and Bronchus</u>									
Male	105	99.2	105.9	(86.6-128.2)					
Female	93	106.1	87.6	(70.7-107.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.8	115.4	(52.7-219.1)	Male	6	4.7	127.1	(46.4-276.6)
Female	3	2.8	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	25	26.1	95.8	(62.0-141.4)	Female	5	3.5	141.1	(45.5-329.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	10.2	107.7	(53.7-192.7)	Female	1	2.7	nc	(nc-nc)
Female	14	9.6	145.5	(79.5-244.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	28.8	100.6	(67.3-144.4)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.5	nc	(nc-nc)	Female	6	5.9	102.2	(37.3-222.4)
Female	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	101	101.4	99.6	(81.1-121.0)
Male	1	1.8	nc	(nc-nc)	Female	89	92.9	95.8	(76.9-117.9)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	14.3	133.0	(80.0-207.7)					
Female	14	13.6	103.2	(56.4-173.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.7	93.2	(44.6-171.4)	Male	2	7.0	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	41	39.8	103.0	(73.9-139.7)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	14.5	68.9	(33.0-126.6)	Female	1	4.0	nc	(nc-nc)
Female	16	14.0	114.5	(65.4-185.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.3	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	6	3.4	174.1	(63.6-379.0)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	40.0	82.4	(56.7-115.7)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	8	5.4	147.9	(63.7-291.5)	<u>Testis</u>				
Female	1	3.2	nc	(nc-nc)	Male	6	1.7	361.1	(131.8-785.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	6.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.8	156.9	(57.3-341.5)	Female	10	8.8	114.0	(54.6-209.7)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	127	144.5	87.9	(73.3-104.6)
Male	4	2.7	nc	(nc-nc)	Female	123	139.2	88.3	(73.4-105.4)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	19.5	123.1	(78.9-183.2)					
Female	24	19.2	125.0	(80.1-186.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.0	145.0	(77.1-247.9)	Male	10	4.9	204.7	(98.0-376.5)
Female	1	3.7	nc	(nc-nc)	Female	9	4.0	227.2	(103.7-431.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	32	29.3	109.2	(74.7-154.1)	Female	2	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.4	105.1	(54.2-183.6)	Female	4	3.1	nc	(nc-nc)
Female	13	13.4	97.1	(51.7-166.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.6	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	29.5	81.2	(52.0-120.9)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	5	3.8	133.3	(42.9-311.0)	<u>Testis</u>				
Female	1	2.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	7	6.5	107.9	(43.2-222.2)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	98	107.6	91.1	(73.9-111.0)
Male	0	1.8	nc	(nc-nc)	Female	106	111.5	95.0	(77.8-114.9)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	15.4	51.9	(22.3-102.2)					
Female	12	16.5	72.8	(37.6-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	41.8	74.1	(50.3-105.2)	Male	21	27.0	77.8	(48.2-119.0)
Female	13	16.6	78.5	(41.8-134.2)	Female	10	23.1	43.2	(20.7-79.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.6	116.7	(55.9-214.7)	Male	3	6.6	nc	(nc-nc)
Female	5	7.3	68.6	(22.1-160.1)	Female	2	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	16	23.1	69.2	(39.5-112.3)
Female	168	159.6	105.3	(89.9-122.4)	Female	22	21.5	102.4	(64.1-155.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.9	nc	(nc-nc)	Male	5	16.1	31.1	(10.0-72.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	59	55.9	105.5	(80.3-136.0)	Female	18	16.2	110.8	(65.6-175.1)
Female	64	58.1	110.2	(84.9-140.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	12.8	101.4	(54.0-173.5)
Male	15	10.9	137.2	(76.7-226.2)	Female	20	14.3	139.5	(85.2-215.5)
Female	3	3.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	132	155.6	84.8	(71.0-100.6)
Male	4	3.9	nc	(nc-nc)	<u>Stomach</u>				
Female	5	3.2	155.6	(50.2-363.2)	Male	13	9.8	132.9	(70.7-227.3)
<u>Kidney & Renal Pelvis</u>					Female	10	6.5	154.3	(73.9-283.7)
Male	25	20.8	120.1	(77.7-177.4)	<u>Testis</u>				
Female	12	13.1	91.5	(47.2-159.8)	Male	9	6.6	137.1	(62.5-260.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	6.5	92.0	(33.6-200.2)	Male	5	7.7	65.0	(20.9-151.7)
Female	3	1.9	nc	(nc-nc)	Female	20	26.0	76.9	(46.9-118.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	14.7	115.4	(67.2-184.8)	Female	30	35.1	85.5	(57.7-122.1)
Female	11	12.0	91.9	(45.8-164.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	525	559.3	93.9	(86.0-102.3)
Male	9	10.3	87.4	(39.9-166.0)	Female	540	566.7	95.3	(87.4-103.7)
Female	3	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	83	76.5	108.4	(86.4-134.4)					
Female	63	79.1	79.6	(61.2-101.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;